20 to 50     : Caution – use only if necessary; start with low dose and increase according to response
10 to 20     : Caution – use only if necessary; start with low dose and increase according to response
<10           : Caution – use only if necessary; start with low dose and increase according to response
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in GFR <10 mL/min
HD                     :Unlikely to be dialysed. Dose as in GFR <10 mL/min
HDF/high flux   :Unlikely to be dialysed. Dose as in GFR <10 mL/min
CAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
None known
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
–
OTHER INFORMATION
Potential to be nephrotoxic due to 5–aminosalicylic acid (5-ASA) component. Both 5-ASA and its acetylated metabolite are rapidly excreted in the urineHalf-life of metabolite is 7 days Less than 3% of an oral dose is absorbed before the drug reaches the colonUnlikely that renal dysfunction will have any important effect on the kinetics of the drugManufacturers recommend that the use of olsalazine in patients with significant renal impairment is contraindicated due to lack of experience of its use in this patient population.